Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2009 Jan;67(1):137-8.
doi: 10.1111/j.1365-2125.2008.03235.x. Epub 2008 Nov 17.

Suggestions for effective contraception in isotretinoin therapy

Antonios I Kanelleas, Steve Thornton, John Berth-Jones
Comment

Suggestions for effective contraception in isotretinoin therapy

Antonios I Kanelleas et al. Br J Clin Pharmacol. 2009 Jan.
No abstract available

PubMed Disclaimer

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Bérard A, Azoulay L, Koren G, Blais L, Perreault S, Oraichi D. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol. 2007;63:196–205. - PMC - PubMed
    1. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med. 1995;333:101–6. - PubMed
    1. Mitchel AA, Van Bennekom CM, Louik C. An assessment of the Accutane (isotretinoin) Pregnancy Prevention Program. [last accessed 4 September 2001]. FDA Dermatologic Drugs Advisory Committee Meeting, Gaithersburgh, MD, September 18, 2000. Available at http://www.fda.gov/ohrms/dockets/ac/00/slides/3639s1i.ppt.
    1. Cunliffe WJ, van de Kerkhof PC, Caputo R, Cavicchini S, Cooper A, Fyrand OL, Gollnick H, Layton AM, Leyden JJ, Mascaro JM, Ortonne JP, Shalita A. Roaccutane treatment guidelines: results of an international survey. Dermatology. 1997;194:351–7. - PubMed
    1. Committee for Proprietary Medicinal Products (CPMP) Committee for Proprietary Medicinal Products (CPMP) summary information on a referral opinion following an arbitration pursuant to Article 29 of Directive 2001/83/EC, for Isotretinoin/Lurantan/Trivane/Rexidal/Scheritonin (see Annex I). International Non-Proprietary Name (INN): Isotretinoin. London, 17 October 2003. CPMP/2811/03.